Vitamin D in Bronchiolitis Obliterans Syndrome - Full Text View

Purpose

Vitamin D deficiency occurs in around 50% of our transplant population. Preventive treatment with Vitamin D (D-cure) can reduce the prevalence of Bronchiolitis Obliterans Syndrome after lung transplantation

Condition	Intervention	Phase
Allograft Rejection Lung Transplantation Bronchiolitis Obliterans	Drug: Vitamin D	Phase 4


Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Prevention
Official Title:	A Randomized Double Blind Placebo Controlled Trial With Vitamin D to Prevent Bronchiolitis Obliterans Syndrome After Lung Transplantation

Resource links provided by NLM:

MedlinePlus related topics: Lung Transplantation Vitamin D

Drug Information available for: Vitamin D

Genetic and Rare Diseases Information Center resources: Bronchiolitis Obliterans

U.S. FDA Resources

Further study details as provided by Universitaire Ziekenhuizen Leuven:

Primary Outcome Measures:

Prevalence of Bronchiolitis Obliterans syndrome (BOS) (grade 1) at 2 years after transplantation [ Time Frame: 2 years after transplantation ] [ Designated as safety issue: No ]
BOS= decline in forced expiratory volume in 1 second (FEV1) with at least 80% compared to the best post-operative value
Prevalence of BOS (grade 1) at 3 years after transplantation [ Time Frame: 3 years after transplantation ] [ Designated as safety issue: No ]
her-evaluation of data

Secondary Outcome Measures:

Bronchoalveolar lavage [ Time Frame: during 2 and 3y of follow-up ] [ Designated as safety issue: No ]
cellularity, protein and mRNA concentration and microbiology
Peripheral blood [ Time Frame: During 2 and 3 years of follow-up ] [ Designated as safety issue: No ]
Protein and mRNA concentration, cellularity
Rejection rates [ Time Frame: During 2 and 3 years of follow-up ] [ Designated as safety issue: No ]
Acute rejection and lymphocytic bronchiolitis rates
Reflux [ Time Frame: During 2 and 3 years of follow-up ] [ Designated as safety issue: No ]
clinical and biochemical approach
Infection rates [ Time Frame: During 2 and 3 years of follow-up ] [ Designated as safety issue: No ]
cytomegalovirus (CMV) and non- CMV infection rates


Estimated Enrollment:	100
Study Start Date:	October 2010
Estimated Study Completion Date:	October 2015
Estimated Primary Completion Date:	October 2014 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Placebo Comparator: Placebo Olive oil	Drug: Vitamin D Every month 100.000 units of vitamin D in syringe Exacta-Med Oral Dispenser during 2 years and re-evaluation after 3 years Other Name: D-Cure
Experimental: Vitamin D Addition of D-cure (100.000U) to standard care	Drug: Vitamin D Every month 100.000 units of vitamin D in syringe Exacta-Med Oral Dispenser during 2 years and re-evaluation after 3 years Other Name: D-Cure

Detailed Description:

Prospective, interventional, randomized, double-blind, placebo-controlled trial.
Clinical setting (tertiary University Hospital).
Investigator-driven, no pharmaceutical sponsor.
Lung transplant recipients.
Add-on of study-drug (placebo or vitamin D) to 'standard of care' (standardized, routine immunosuppressive and infectious prophylactic protocol).
1:1 inclusion ratio (placebo:Vitamin D).
Randomisation at discharge after informed consent.

Eligibility


Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Stable LTx recipients at discharge after transplantation.
Signed informed consent
Adult (age at least 18 years old at moment of transplantation)
Able to take oral medication

Exclusion Criteria:

Prolonged and/or complicated Intensive care unit-course after transplantation.
Early (<30 days post-transplant) post-operative death
Major suture problems (airway stenosis or stent)
Retransplantation (lung)
Previous transplantation (solid organ)
Multi-organ transplantation (lung+ other solid organ)

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01212406

Locations


Belgium
UZ Gasthuisberg
Leuven, Belgium, 3000

Sponsors and Collaborators

Universitaire Ziekenhuizen Leuven

Katholieke Universiteit Leuven

Investigators


Principal Investigator:	Geert M Verleden, MD, PhD	UZ gasthuisberg

More Information

Publications:

Ramirez AM, Wongtrakool C, Welch T, Steinmeyer A, Zügel U, Roman J. Vitamin D inhibition of pro-fibrotic effects of transforming growth factor beta1 in lung fibroblasts and epithelial cells. J Steroid Biochem Mol Biol. 2010 Feb 15;118(3):142-50. doi: 10.1016/j.jsbmb.2009.11.004. Epub 2009 Nov 17.

Zittermann A, Schleithoff SS, Götting C, Fuchs U, Kuhn J, Kleesiek K, Tenderich G, Koerfer R. Calcitriol deficiency and 1-year mortality in cardiac transplant recipients. Transplantation. 2009 Jan 15;87(1):118-24. doi: 10.1097/TP.0b013e31818c2708.

Janssens W, Bouillon R, Claes B, Carremans C, Lehouck A, Buysschaert I, Coolen J, Mathieu C, Decramer M, Lambrechts D. Vitamin D deficiency is highly prevalent in COPD and correlates with variants in the vitamin D-binding gene. Thorax. 2010 Mar;65(3):215-20. doi: 10.1136/thx.2009.120659. Epub 2009 Dec 8.

Vanaudenaerde BM, Meyts I, Vos R, Geudens N, De Wever W, Verbeken EK, Van Raemdonck DE, Dupont LJ, Verleden GM. A dichotomy in bronchiolitis obliterans syndrome after lung transplantation revealed by azithromycin therapy. Eur Respir J. 2008 Oct;32(4):832-43. doi: 10.1183/09031936.00134307. Review.

Estenne M, Maurer JR, Boehler A, Egan JJ, Frost A, Hertz M, Mallory GB, Snell GI, Yousem S. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant. 2002 Mar;21(3):297-310. Review.


Responsible Party:	Universitaire Ziekenhuizen Leuven
ClinicalTrials.gov Identifier:	NCT01212406 History of Changes
Other Study ID Numbers:	VIT001
Study First Received:	September 28, 2010
Last Updated:	December 13, 2013
Health Authority:	Belgium: Federal Agency for Medicinal Products and Health Products Belgium: Ethics Committee

Keywords provided by Universitaire Ziekenhuizen Leuven:


Organ rejection Lung transplantation Bronchiolitis Obliterans Vitamin D Prevention

Additional relevant MeSH terms:


Bronchiolitis Bronchiolitis Obliterans Bronchial Diseases Bronchitis Lung Diseases Lung Diseases, Obstructive Respiratory Tract Diseases Respiratory Tract Infections	Ergocalciferols Vitamin D Vitamins Bone Density Conservation Agents Growth Substances Micronutrients Pharmacologic Actions Physiological Effects of Drugs

ClinicalTrials.gov processed this record on February 27, 2015

Vitamin D in Bronchiolitis Obliterans Syndrome (VIT001)